Evidence map›Paper›PMID 39931379›Full record

ArticleFrontiers in microbiology2025

Cost-effective whole-cell biosynthesis of ursodeoxycholic acid using engineered

Xue Zhang, Jiagang Xin, Mengyu Liu, Yue Zhang, Haoni Luan, Wei Feng, Fei Wang, Wei Xu, Peng Song

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xue ZhangSchool of Pharmaceutical Sciences and Food Engineering, Liaocheng University, Liaocheng, China.
Jiagang XinShandong Aobo Biotech Co. Ltd., Liaocheng, China.
Mengyu LiuSchool of Pharmaceutical Sciences and Food Engineering, Liaocheng University, Liaocheng, China.
Yue ZhangSchool of Pharmaceutical Sciences and Food Engineering, Liaocheng University, Liaocheng, China.
Haoni LuanSchool of Pharmaceutical Sciences and Food Engineering, Liaocheng University, Liaocheng, China.
Wei FengSchool of Pharmaceutical Sciences and Food Engineering, Liaocheng University, Liaocheng, China.
Fei WangSchool of Pharmaceutical Sciences and Food Engineering, Liaocheng University, Liaocheng, China.
Wei XuSchool of Pharmaceutical Sciences and Food Engineering, Liaocheng University, Liaocheng, China.
Peng SongSchool of Pharmaceutical Sciences and Food Engineering, Liaocheng University, Liaocheng, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ursodeoxycholic acid (UDCA) can be used as a drug to treat various liver and bile diseases. Currently, the biological synthesis of UDCA is predominantly conducted via a two-step enzymatic process in which synthesis is catalyzed by 7α-hydroxysteroid dehydrogenase (7α-HSDH) and 7β-hydroxysteroid dehydrogenase (7β-HSDH) in succession, utilizing chenodeoxycholic acid (CDCA) as the substrate. In this study, an engineered

Indexed as

7α-hydroxysteroid dehydrogenase7β-hydroxysteroid dehydrogenasechenodeoxycholic acidglucose dehydrogenaselactate dehydrogenaseursodeoxycholic acidwhole-cell catalysis

Identifiers

PMID39931379
PMCPMC11808682

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.